Managing Anticoagulation Therapy
Guides anticoagulation selection, dosing, monitoring, and bridging protocols for warfarin, DOACs, and heparin therapy.
Why This Skill Exists
Anticoagulants are consistently ranked among the top high-alert medications by the Institute for Safe Medication Practices (ISMP). Warfarin alone accounts for more emergency department visits for adverse drug events than any other medication class in patients over 65. Dosing errors, inadequate monitoring, and improper periprocedural management lead to catastrophic bleeding events or thromboembolic strokes.
The complexity of anticoagulation management spans multiple dimensions: selecting the appropriate agent based on indication (atrial fibrillation, VTE, mechanical heart valve), renal-adjusted dosing for DOACs, INR-based warfarin titration, weight-based heparin nomograms, bridging decisions for surgical patients, and reversal agent selection during active bleeding. The Joint Commission National Patient Safety Goal NPSG.03.05.01 specifically addresses anticoagulation safety, and accredited institutions must maintain anticoagulation management protocols. Pharmacist-managed anticoagulation clinics consistently demonstrate superior time-in-therapeutic-range (TTR) compared to physician-only management.
Checkpoint A: Pre-Draft Intake (Mandatory)
- What is the indication for anticoagulation? (Default: atrial fibrillation; alternatives: VTE treatment, VTE prophylaxis, mechanical heart valve, LV thrombus)
- Which anticoagulant is being used or considered? (Default: review all options for indication)
- What is the patient's renal function (SCr, CrCl by Cockcroft-Gault, eGFR)? (Default: request labs)
- What is the patient's weight? (Default: actual body weight for heparin dosing)
- Is there an upcoming procedure requiring bridging assessment? (Default: no)
- What is the patient's bleeding risk score (HAS-BLED for AF)? (Default: calculate from available data)
- What is the patient's stroke risk score (CHA₂DS₂-VASc for AF)? (Default: calculate from available data)
- Are there concomitant antiplatelet agents, NSAIDs, or interacting drugs? (Default: check active med list)
Documents to Request
- Complete medication profile including OTC/herbals
- Labs: CBC with platelet count, PT/INR, aPTT, SCr/BUN, LFTs, anti-Xa level if applicable
- CHA₂DS₂-VASc and HAS-BLED score components
- Surgical/procedural schedule if applicable
- Prior anticoagulation history (INR diary, prior bleeding/clotting events)
- Body weight (actual and adjusted if obese)
Step 1: Indication-Based Agent Selection
Match indication to appropriate anticoagulant options:
| Indication |
Preferred Agents |
Contraindicated |
| Non-valvular AF |
Apixaban, rivaroxaban, dabigatran, edoxaban, warfarin |
— |
| Mechanical heart valve |
Warfarin (target INR 2.5-3.5) |
All DOACs (RE-ALIGN trial) |
| Acute VTE treatment |
Apixaban, rivaroxaban (single-drug), LMWH→dabigatran/edoxaban, LMWH→warfarin |
— |
| VTE prophylaxis (surgical) |
Enoxaparin, rivaroxaban, apixaban (indication-specific) |
— |
| Heparin-induced thrombocytopenia |
Argatroban, bivalirudin |
Heparin, LMWH, warfarin (acute phase) |
| Antiphospholipid syndrome (triple-positive) |
Warfarin (INR 2-3) |
DOACs (TRAPS trial) |
Calculate risk stratification scores:
- CHA₂DS₂-VASc: CHF(1), HTN(1), Age≥75(2), DM(1), Stroke/TIA(2), Vascular disease(1), Age 65-74(1), Sex female(1)
- HAS-BLED: HTN(1), Abnormal renal/liver(1 each), Stroke(1), Bleeding(1), Labile INR(1), Elderly>65(1), Drugs/alcohol(1 each)
Step 2: Dosing and Renal Adjustment
Warfarin: Initiate 5 mg daily (2.5 mg for elderly, malnourished, liver disease, CYP2C9/VKORC1 polymorphisms). Check INR at day 3-5, adjust by 10-20% increments.
DOAC Renal-Adjusted Dosing:
| Drug |
Standard Dose (AF) |
Renal Adjustment |
| Apixaban |
5 mg BID |
2.5 mg BID if ≥2 of: age ≥80, weight ≤60 kg, SCr ≥1.5 |
| Rivaroxaban |
20 mg daily with food |
15 mg daily if CrCl 15-50 mL/min |
| Dabigatran |
150 mg BID |
75 mg BID if CrCl 15-30 mL/min; avoid if <15 |
| Edoxaban |
60 mg daily |
30 mg daily if CrCl 15-50 mL/min, weight ≤60 kg, or P-gp inhibitor |
Weight-based heparin nomogram (VTE): 80 units/kg bolus → 18 units/kg/hour infusion. Check aPTT at 6 hours. Adjust per institution-specific nomogram targeting aPTT 1.5-2.5x control or anti-Xa 0.3-0.7 IU/mL.
Enoxaparin: 1 mg/kg SC BID (treatment) or 40 mg SC daily (prophylaxis). Reduce to 1 mg/kg daily if CrCl <30 mL/min. Monitor anti-Xa in obesity (>120 kg), renal impairment, and pregnancy.
Step 3: Monitoring and Therapeutic Targets
| Agent |
Monitoring Parameter |
Target |
Frequency |
| Warfarin |
PT/INR |
2.0-3.0 (most); 2.5-3.5 (mechanical valve) |
Daily inpatient → weekly → monthly |
| Heparin UFH |
aPTT or anti-Xa |
aPTT 1.5-2.5x control; anti-Xa 0.3-0.7 |
q6h until stable, then daily |
| Enoxaparin |
Anti-Xa (select populations) |
0.5-1.0 IU/mL (BID dosing peak, 4h post) |
At steady state in special populations |
| DOACs |
Generally not monitored |
Drug-specific anti-Xa or dTT if needed |
Pre-procedure or suspected toxicity |
Monitor for bleeding: daily hemoglobin, stool guaiac, urinalysis, neurological checks for ICH risk.
Step 4: Periprocedural Bridging Protocol
Apply the BRIDGE trial framework for AF patients on warfarin:
- Low thromboembolic risk (CHA₂DS₂-VASc 1-4): No bridging; hold warfarin 5 days pre-procedure
- High thromboembolic risk (mechanical valve, recent VTE <3 months, CHA₂DS₂-VASc ≥7): Consider bridging with enoxaparin 1 mg/kg BID, last dose 24h pre-procedure
DOAC perioperative management: Hold based on renal function and bleeding risk:
- Low bleeding risk: hold 24-48 hours
- High bleeding risk: hold 48-72 hours
- Dabigatran in CrCl <50: hold 72-96 hours
Step 5: Reversal and Emergency Management
| Agent |
Reversal |
Dose |
| Warfarin |
Vitamin K (IV), 4-factor PCC |
Vitamin K 10 mg IV; PCC per INR-based dosing |
| Dabigatran |
Idarucizumab |
5 g IV (two 2.5 g boluses) |
| Apixaban/Rivaroxaban |
Andexanet alfa or 4-factor PCC |
Andexanet per package insert; PCC 25-50 units/kg |
| UFH |
Protamine |
1 mg per 100 units heparin (max 50 mg) |
| Enoxaparin |
Protamine (partial) |
1 mg per 1 mg enoxaparin (<8h); 60-80% reversal |
Checkpoint B: Post-Draft Alignment (Mandatory)
- Is the selected agent appropriate for the indication (no DOACs for mechanical valves)?
- Has renal function been calculated and dose adjusted per CrCl thresholds?
- Are drug interactions with the anticoagulant identified and managed?
- Is the monitoring plan specific with parameters, targets, and frequencies?
- Has bleeding risk been formally scored and documented?
Quality Audit
Guidelines
- Always use Cockcroft-Gault CrCl (not CKD-EPI eGFR) for DOAC dose adjustment—trials used this equation
- Never use DOACs in mechanical heart valve patients (contraindicated per RE-ALIGN)
- Warfarin TTR should exceed 65%; consider DOAC switch if persistently below target
- Weight-based heparin dosing should use actual body weight; cap initial bolus at institutional limits for morbid obesity
- Document CHA₂DS₂-VASc, HAS-BLED, and rationale when anticoagulation is deferred despite indication
- Periprocedural bridging is generally NOT recommended for AF patients at moderate thromboembolic risk per BRIDGE trial
- Always verify DOAC dose is not inappropriately reduced—underdosing increases stroke risk without reducing bleeding
- Ensure reversal agents are stocked and protocols are accessible for emergency bleeding management
1---2name: managing-anticoagulation-therapy3description: Guides anticoagulation selection, dosing, monitoring, and bridging protocols. Use when managing warfarin, DOACs, or heparin therapy, or planning periprocedural anticoagulation.4---5
6# Managing Anticoagulation Therapy
7
8Guides anticoagulation selection, dosing, monitoring, and bridging protocols for warfarin, DOACs, and heparin therapy.
9
10## Why This Skill Exists
11
12Anticoagulants are consistently ranked among the top high-alert medications by the Institute for Safe Medication Practices (ISMP). Warfarin alone accounts for more emergency department visits for adverse drug events than any other medication class in patients over 65. Dosing errors, inadequate monitoring, and improper periprocedural management lead to catastrophic bleeding events or thromboembolic strokes.
13
14The complexity of anticoagulation management spans multiple dimensions: selecting the appropriate agent based on indication (atrial fibrillation, VTE, mechanical heart valve), renal-adjusted dosing for DOACs, INR-based warfarin titration, weight-based heparin nomograms, bridging decisions for surgical patients, and reversal agent selection during active bleeding. The Joint Commission National Patient Safety Goal NPSG.03.05.01 specifically addresses anticoagulation safety, and accredited institutions must maintain anticoagulation management protocols. Pharmacist-managed anticoagulation clinics consistently demonstrate superior time-in-therapeutic-range (TTR) compared to physician-only management.
15
16---
17
18## Checkpoint A: Pre-Draft Intake (Mandatory)
19
201. What is the indication for anticoagulation? (Default: atrial fibrillation; alternatives: VTE treatment, VTE prophylaxis, mechanical heart valve, LV thrombus)
212. Which anticoagulant is being used or considered? (Default: review all options for indication)
223. What is the patient's renal function (SCr, CrCl by Cockcroft-Gault, eGFR)? (Default: request labs)
234. What is the patient's weight? (Default: actual body weight for heparin dosing)
245. Is there an upcoming procedure requiring bridging assessment? (Default: no)
256. What is the patient's bleeding risk score (HAS-BLED for AF)? (Default: calculate from available data)
267. What is the patient's stroke risk score (CHA₂DS₂-VASc for AF)? (Default: calculate from available data)
278. Are there concomitant antiplatelet agents, NSAIDs, or interacting drugs? (Default: check active med list)
28
29### Documents to Request
30
31- Complete medication profile including OTC/herbals
32- Labs: CBC with platelet count, PT/INR, aPTT, SCr/BUN, LFTs, anti-Xa level if applicable
33- CHA₂DS₂-VASc and HAS-BLED score components
34- Surgical/procedural schedule if applicable
35- Prior anticoagulation history (INR diary, prior bleeding/clotting events)
36- Body weight (actual and adjusted if obese)
37
38---
39
40## Step 1: Indication-Based Agent Selection
41
42Match indication to appropriate anticoagulant options:
43
44| Indication | Preferred Agents | Contraindicated |
45|---|---|---|
46| Non-valvular AF | Apixaban, rivaroxaban, dabigatran, edoxaban, warfarin | — |
47| Mechanical heart valve | Warfarin (target INR 2.5-3.5) | All DOACs (RE-ALIGN trial) |
48| Acute VTE treatment | Apixaban, rivaroxaban (single-drug), LMWH→dabigatran/edoxaban, LMWH→warfarin | — |
49| VTE prophylaxis (surgical) | Enoxaparin, rivaroxaban, apixaban (indication-specific) | — |
50| Heparin-induced thrombocytopenia | Argatroban, bivalirudin | Heparin, LMWH, warfarin (acute phase) |
51| Antiphospholipid syndrome (triple-positive) | Warfarin (INR 2-3) | DOACs (TRAPS trial) |
52
53Calculate risk stratification scores:
54- **CHA₂DS₂-VASc:** CHF(1), HTN(1), Age≥75(2), DM(1), Stroke/TIA(2), Vascular disease(1), Age 65-74(1), Sex female(1)
55- **HAS-BLED:** HTN(1), Abnormal renal/liver(1 each), Stroke(1), Bleeding(1), Labile INR(1), Elderly>65(1), Drugs/alcohol(1 each)
56
57---
58
59## Step 2: Dosing and Renal Adjustment
60
61**Warfarin:** Initiate 5 mg daily (2.5 mg for elderly, malnourished, liver disease, CYP2C9/VKORC1 polymorphisms). Check INR at day 3-5, adjust by 10-20% increments.
62
63**DOAC Renal-Adjusted Dosing:**
64
65| Drug | Standard Dose (AF) | Renal Adjustment |
66|---|---|---|
67| Apixaban | 5 mg BID | 2.5 mg BID if ≥2 of: age ≥80, weight ≤60 kg, SCr ≥1.5 |
68| Rivaroxaban | 20 mg daily with food | 15 mg daily if CrCl 15-50 mL/min |
69| Dabigatran | 150 mg BID | 75 mg BID if CrCl 15-30 mL/min; avoid if <15 |
70| Edoxaban | 60 mg daily | 30 mg daily if CrCl 15-50 mL/min, weight ≤60 kg, or P-gp inhibitor |
71
72**Weight-based heparin nomogram (VTE):** 80 units/kg bolus → 18 units/kg/hour infusion. Check aPTT at 6 hours. Adjust per institution-specific nomogram targeting aPTT 1.5-2.5x control or anti-Xa 0.3-0.7 IU/mL.
73
74**Enoxaparin:** 1 mg/kg SC BID (treatment) or 40 mg SC daily (prophylaxis). Reduce to 1 mg/kg daily if CrCl <30 mL/min. Monitor anti-Xa in obesity (>120 kg), renal impairment, and pregnancy.
75
76---
77
78## Step 3: Monitoring and Therapeutic Targets
79
80| Agent | Monitoring Parameter | Target | Frequency |
81|---|---|---|---|
82| Warfarin | PT/INR | 2.0-3.0 (most); 2.5-3.5 (mechanical valve) | Daily inpatient → weekly → monthly |
83| Heparin UFH | aPTT or anti-Xa | aPTT 1.5-2.5x control; anti-Xa 0.3-0.7 | q6h until stable, then daily |
84| Enoxaparin | Anti-Xa (select populations) | 0.5-1.0 IU/mL (BID dosing peak, 4h post) | At steady state in special populations |
85| DOACs | Generally not monitored | Drug-specific anti-Xa or dTT if needed | Pre-procedure or suspected toxicity |
86
87Monitor for bleeding: daily hemoglobin, stool guaiac, urinalysis, neurological checks for ICH risk.
88
89---
90
91## Step 4: Periprocedural Bridging Protocol
92
93Apply the BRIDGE trial framework for AF patients on warfarin:
94- **Low thromboembolic risk (CHA₂DS₂-VASc 1-4):** No bridging; hold warfarin 5 days pre-procedure
95- **High thromboembolic risk (mechanical valve, recent VTE <3 months, CHA₂DS₂-VASc ≥7):** Consider bridging with enoxaparin 1 mg/kg BID, last dose 24h pre-procedure
96
97**DOAC perioperative management:** Hold based on renal function and bleeding risk:
98- Low bleeding risk: hold 24-48 hours
99- High bleeding risk: hold 48-72 hours
100- Dabigatran in CrCl <50: hold 72-96 hours
101
102---
103
104## Step 5: Reversal and Emergency Management
105
106| Agent | Reversal | Dose |
107|---|---|---|
108| Warfarin | Vitamin K (IV), 4-factor PCC | Vitamin K 10 mg IV; PCC per INR-based dosing |
109| Dabigatran | Idarucizumab | 5 g IV (two 2.5 g boluses) |
110| Apixaban/Rivaroxaban | Andexanet alfa or 4-factor PCC | Andexanet per package insert; PCC 25-50 units/kg |
111| UFH | Protamine | 1 mg per 100 units heparin (max 50 mg) |
112| Enoxaparin | Protamine (partial) | 1 mg per 1 mg enoxaparin (<8h); 60-80% reversal |
113
114---
115
116## Checkpoint B: Post-Draft Alignment (Mandatory)
117
1181. Is the selected agent appropriate for the indication (no DOACs for mechanical valves)?
1192. Has renal function been calculated and dose adjusted per CrCl thresholds?
1203. Are drug interactions with the anticoagulant identified and managed?
1214. Is the monitoring plan specific with parameters, targets, and frequencies?
1225. Has bleeding risk been formally scored and documented?
123
124---
125
126## Quality Audit
127
128- [ ] Indication verified and matched to guideline-recommended agent
129- [ ] CHA₂DS₂-VASc and HAS-BLED scores calculated (for AF patients)
130- [ ] Renal function assessed by Cockcroft-Gault for DOAC dosing
131- [ ] Correct dose selected with renal/weight/age adjustments applied
132- [ ] Drug interactions screened (CYP3A4/P-gp for DOACs, CYP2C9/VKORC1 for warfarin)
133- [ ] Monitoring plan includes specific lab parameters and frequency
134- [ ] Bridging plan documented for periprocedural patients with risk justification
135- [ ] Reversal strategy identified and agents available for the selected anticoagulant
136- [ ] Patient education on signs of bleeding and dietary considerations (warfarin/vitamin K)
137- [ ] Transition plan documented for hospital discharge or agent switching
138- [ ] Duration of therapy defined (3 months VTE vs. indefinite AF)
139- [ ] ISMP high-alert medication safeguards addressed
140
141---
142
143## Guidelines
144
145- Always use Cockcroft-Gault CrCl (not CKD-EPI eGFR) for DOAC dose adjustment—trials used this equation
146- Never use DOACs in mechanical heart valve patients (contraindicated per RE-ALIGN)
147- Warfarin TTR should exceed 65%; consider DOAC switch if persistently below target
148- Weight-based heparin dosing should use actual body weight; cap initial bolus at institutional limits for morbid obesity
149- Document CHA₂DS₂-VASc, HAS-BLED, and rationale when anticoagulation is deferred despite indication
150- Periprocedural bridging is generally NOT recommended for AF patients at moderate thromboembolic risk per BRIDGE trial
151- Always verify DOAC dose is not inappropriately reduced—underdosing increases stroke risk without reducing bleeding
152- Ensure reversal agents are stocked and protocols are accessible for emergency bleeding management
CaseMark